MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts' consensus: "Hold" — Five analysts cover MiNK Therapeutics (one sell, two hold, one buy, one strong buy) with an average 12-month price target of $35.00.
• MiNK reported a Q1 EPS of −$0.54, beating estimates by $0.14 (consensus −$0.68), while analysts project a full-year EPS of about −3.27.
• The stock opened at $11.81 (reported up 8.5%), with a market cap of $58.7M and a 52-week range of $6.34–$76.00; institutional ownership is low (2.87%), and Geode Capital increased its stake to 14,247 shares.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received an average rating of "Hold" from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $35.00.

A number of research analysts recently commented on INKT shares. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of MiNK Therapeutics in a research note on Wednesday, April 1st. Weiss Ratings raised MiNK Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. Finally, Wall Street Zen raised MiNK Therapeutics to a "sell" rating in a research note on Saturday, April 25th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,247 shares of the company's stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. 2.87% of the stock is owned by institutional investors.

MiNK Therapeutics Stock Up 8.5%

INKT opened at $11.81 on Thursday. The stock has a market cap of $58.70 million, a PE ratio of -3.98 and a beta of 0.35. MiNK Therapeutics has a 52 week low of $6.34 and a 52 week high of $76.00. The business's fifty day simple moving average is $10.99 and its 200 day simple moving average is $11.84.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported ($0.54) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.14. As a group, equities analysts anticipate that MiNK Therapeutics will post -3.27 earnings per share for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company's proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK's preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.